| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TMOD3 |
| Uniprot No | Q9NYL9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-352aa |
| 氨基酸序列 | MALPFRKDLEKYKDLDEDELLGNLSETELKQLETVLDDLDPENALLPAGFRQKNQTSKSTTGPFDREHLLSYLEKEALEHKDREDYVPYTGEKKGKIFIPKQKPVQTFTEEKVSLDPELEEALTSASDTELCDLAAILGMHNLITNTKFCNIMGSSNGVDQEHFSNVVKGEKILPVFDEPPNPTNVEESLKRTKENDAHLVEVNLNNIKNIPIPTLKDFAKALETNTHVKCFSLAATRSNDPVATAFAEMLKVNKTLKSLNVESNFITGVGILALIDALRDNETLAELKIDNQRQQLGTAVELEMAKMLEENTNILKFGYQFTQQGPRTRAANAITKNNDLVRKRRVEGDHQ |
| 预测分子量 | 66.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TMOD3重组蛋白的3篇参考文献示例(文献信息为模拟示例，非真实存在)：
1. **文献名称**: "Recombinant TMOD3 regulates actin filament stability in vitro"
**作者**: Smith A, et al.
**摘要**: 研究利用大肠杆菌表达系统纯化重组TMOD3蛋白，通过体外实验证明其通过结合肌动蛋白丝末端抑制解聚，调控细胞骨架动态平衡。
2. **文献名称**: "Structural analysis of tropomodulin 3 reveals its role in erythrocyte membrane organization"
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析重组人源TMOD3的晶体结构，发现其与原肌球蛋白的相互作用界面，揭示了TMOD3在红细胞膜稳定性中的分子机制。
3. **文献名称**: "TMOD3 overexpression disrupts cardiomyocyte sarcomere assembly"
**作者**: Kimura T, et al.
**摘要**: 利用腺病毒载体在心肌细胞中表达重组TMOD3.发现其异常表达导致肌节组装紊乱，提示TMOD3在心脏发育中的精细调控作用。
注：以上内容为学术示例，实际文献需通过PubMed/Google Scholar以关键词“TMOD3 recombinant”“tropomodulin 3 expression”检索获取。
**Background of TMOD3 Recombinant Protein**
Tropomodulin 3 (TMOD3) is a member of the tropomodulin family of actin-binding proteins that regulate cytoskeleton dynamics by stabilizing actin filaments. It is widely expressed in non-muscle tissues, distinguishing it from its paralogs TMOD1 and TMOD2. which are predominantly found in muscle cells. TMOD3 plays a critical role in maintaining actin filament stability by acting as a "capping" protein at the pointed ends of actin filaments, thereby modulating their elongation and depolymerization. This function is essential for cellular processes such as cell morphogenesis, intracellular trafficking, and cell motility.
The recombinant TMOD3 protein is produced using biotechnological methods, often through expression in bacterial (e.g., *E. coli*) or mammalian cell systems, followed by purification via affinity chromatography. Recombinant TMOD3 retains its native biochemical properties, enabling researchers to study its interactions with actin, tropomyosin, and other cytoskeletal components *in vitro*. Studies have linked TMOD3 dysregulation to pathological conditions, including cancer metastasis, neurological disorders, and erythrocyte membrane defects, highlighting its biomedical relevance.
Recent research focuses on TMOD3's role in epithelial-mesenchymal transition (EMT) and its involvement in signaling pathways, such as Rho GTPase-mediated cytoskeletal remodeling. Recombinant TMOD3 serves as a valuable tool for structural studies, drug screening, and elucidating mechanisms underlying cytoskeletal disorders. Its applications extend to developing therapeutic strategies targeting actin-dependent cellular processes in diseases like cancer and neurodegeneration.
In summary, TMOD3 recombinant protein is a key reagent for dissecting actin dynamics and exploring its physiological and pathological roles, offering potential insights into novel therapeutic interventions.
×
